[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-383290-105":59,"doc-detail-383290-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","precision-medicine-programmatic-precision-oncology-decision-support-for-patients-with-gastrointestinal-cancer-abstract","PRECISION MEDICINE - Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer - Abstract","","Precision oncology care depends on navigating a rapidly changing landscape of targeted therapeutics and molecular biomarkers that can be difficult for oncologists to manage independently. A precision oncology decision support system, GI TARGET, was developed and implemented at the Dana-Farber Gastrointestinal Cancer Center. A multidisciplinary team reviewed tumor molecular profiling, matched patients to clinical trials using MatchMiner, suggested on- and off-label targeted options, and considered additional molecular testing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/precision-medicine-programmatic-precision-oncology-decision-support-for-patients-with-gastrointestinal-cancer-abstract/383290/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/precision-medicine-programmatic-precision-oncology-decision-support-for-patients-with-gastrointestinal-cancer-abstract/383290.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-26","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the paper address in precision oncology?","Question",{"text":112,"@type":113},"It addresses the difficulty oncologists face in navigating a rapidly evolving precision oncology landscape of targeted therapies and molecular biomarkers when care requires comprehensive, molecularly informed decisions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did GI TARGET support clinical decisions for gastrointestinal cancer patients?",{"text":117,"@type":113},"The system used tumor molecular profiling reviewed by a multidisciplinary team, computationally matched patients to clinical trials via MatchMiner, suggested on-label and off-label targeted therapy options, and recommended additional or orthogonal molecular testing when appropriate.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key outcomes reported from implementing the program?",{"text":121,"@type":113},"For 506 reviewed patients, the program provided clinical recommendations including at least one precision medicine clinical trial for 80% of patients, resulting in 24 enrollments, alongside on-label and off-label targeted therapy recommendations and guidance for additional testing for 42% of patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},383290,1790388731,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","original reports  \nPRECISION MEDICINE  \nProgrammatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer  \nRachel B. Keller, PhD1; Tali Mazor, PhD2; Lynette Sholl, MD3; Andrew J. Aguirre, MD, PhD1,4; Harshabad Singh, MBBS1;  \nNilay Sethi, MD, PhD1; Adam Bass, MD1; Ankur K. Nagaraja, MD1; Lauren K. Brais, MPH1; Emma Hill, BS1; Connor Hennessey, BA1; Margaret Cusick, BS1; Catherine Del Vecchio Fitz, PhD2; Zachary Zwiesler, MS2; Ethan Siegel, BA2; Andrea Ovalle, BS2;  \nPavel Trukhanov, MSc2; Jason Hansel, BA2; Geoffrey I. Shapiro, MD, PhD1; Thomas A. Abrams, MD1; Leah H. Biller, MD1; Jennifer A. Chan, MD, MPH1; James M. Cleary, MD, PhD1; Steven M. Corsello, MD1; Andrea C. Enzinger, MD1; Peter C. Enzinger, MD1; Robert J. Mayer, MD1; Nadine J. McCleary, MD, MPH1; Jeffrey A. Meyerhardt, MD, MPH1; Kimmie Ng, MD, MPH1; Anuj K. Patel, MD1; Kimberley J. Perez, MD1; Osama E. Rahma, MD1; Douglas A. Rubinson, MD, PhD1; Jeffrey S. Wisch, MD1; Matthew B. Yurgelun, MD1; Michael J. Hassett, MD, MPH1; Laura MacConaill, PhD3; Deborah Schrag, MD, MPH1; Ethan Cerami, PhD2; Brian M. Wolpin, MD, MPH1; Jonathan A. Nowak, MD, PhD3; and Marios Giannakis, MD, PhD1,4  \nabstract  \nASSOCIATED CONTENT  \nData Supplement  \nAuthor affiliationsand support information (if applicable) appear atthe end of this article.  \nAccepted on November 22, 2022 and published at  \n[ascopubs.org/journal/](ascopubs.org/journal/)[ ](ascopubs.org/journal/)po on January 12, 2023: DOI [https://doi](https://doi). org/10.1200/PO.22 . 00342  \nPURPOSE With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape of precision oncology, which can be challenging for oncologists to navigate alone.  \nMETHODS We developed and implemented a precision oncology decision support system, GI TARGET,(Gastrointestinal Treatment Assistance Regarding Genomic Evaluation of Tumors) within the Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute. With a multidisciplinary team, we systematically reviewed tumor molecular profiling for GI tumors and provided molecularly informed clinical recommendations, which included identifying appropriate clinical trials aided by the computational matching platform MatchMiner, suggesting targeted therapy options on or off the US Food and Drug Administration–approved label, and consideration of additional or orthogonal molecular testing.  \nRESULTS We reviewed genomic data and provided clinical recommendations for 506 patients with GI cancer who underwent tumor molecular profiling between January and June 2019 and determined follow-up using the electronic health record. Summary reports were provided to 19 medical oncologists for patients with colorectal (n = 198, 39%), pancreatic (n = 124, 24%), esophagogastric (n = 67, 13%), biliary (n = 40, 8%), and other GI cancers. We recommended ≥ 1 precision medicine clinical trial for 80%(406 of 506) of patients, leading to 24 enrollments. We recommended on-label and off-label targeted therapies for 6%(28 of 506) and 25%(125 of 506) of patients, respectively. Recommendations for additional or orthogonal testing were made for 42%(211 of 506) of patients.  \nCONCLUSION The integration of precision medicine in routine cancer care through a dedicated multidisciplinary molecular tumor board is scalable and sustainable, and implementation of precision oncology recommendations has clinical utility for patients with cancer.  \nJCO Precis Oncol 7:e2200342 . © 2023 by American Society of Clinical Oncology  \nLicensed under the Creative Commons Attribution 4.0 License   \nINTRODUCTION  \nIn parallel with a deepening understanding of the molecular landscapes of cancer, the standards of care in clinical oncology are also evolving. Cancers are driven by heterogeneous molecular alterations across tissues of origin, among individuals with the same cancer diagnosis1 and even ","cbCaiaYfrnhqIWGN","https://ap.wps.com/l/cbCaiaYfrnhqIWGN","pdf",792302,13,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What problem does the paper address in precision oncology?\",\"answer\":\"It addresses the difficulty oncologists face in navigating a rapidly evolving precision oncology landscape of targeted therapies and molecular biomarkers when care requires comprehensive, molecularly informed decisions.\"},{\"question\":\"How did GI TARGET support clinical decisions for gastrointestinal cancer patients?\",\"answer\":\"The system used tumor molecular profiling reviewed by a multidisciplinary team, computationally matched patients to clinical trials via MatchMiner, suggested on-label and off-label targeted therapy options, and recommended additional or orthogonal molecular testing when appropriate.\"},{\"question\":\"What were the key outcomes reported from implementing the program?\",\"answer\":\"For 506 reviewed patients, the program provided clinical recommendations including at least one precision medicine clinical trial for 80% of patients, resulting in 24 enrollments, alongside on-label and off-label targeted therapy recommendations and guidance for additional testing for 42% of patients.\"}]","PRECISION MEDICINE - Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer - Abstract | PDF",1790255712,33]